Skip to Content

Amgen Says Court Upholds Sensipar Patents

From Associated Press (January 7, 2011)

THOUSAND OAKS, Calif. -- Biotech drug maker Amgen Inc. said Friday that a U.S. court upheld the patents supporting its hyperparathyroidism drug Sensipar, blocking a competitor from selling a generic version of the drug until 2018.

Amgen said the U.S. District Court for the District of Delaware upheld three patents on Sensipar, and granted an injunction that stops Teva Pharmaceutical Industries Ltd. from selling its version until the patents expire. Sensipar was first approved in March 2004, and Amgen said the last patent extension protecting the drug will expire in March 2018.

Worldwide sales of Sensipar amounted to $175 million in the third quarter, up 6 percent primarily as a result of increased international demand.

Shares of Amgen rose 43 cents to $56.98 Friday, but slipped 2 cents to $56.96 in aftermarket trading.

Jerusalem-based Teva is the world’s largest maker of generic drugs. Its shares advanced 57 cents to $54.01 and then picked up another 20 cents to $54.21 aftermarket.

Posted: January 2011